Mitsubishi Tanabe notifies Kolon Life Science cancellation of ‘Invossa’ technology agreement

Published: 2017-12-21 16:03:59

Updated: 2017-12-21 16:03:59

Kolon Life Science(CEO Woo-Seok Lee) announced on the 19^th Mitsubishi Tanabe Pharma(MTPC) notified the company cancellation of Invossa technology export and to return the upfront payment of JPY 2.5 billion(approx. KRW 25 billion).

MTPC notified the cancellation because Kolon Life Science did not explain the fact TissueGene, the original developer of Invossa, was considering to change its manuf...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.